6 results about "Norvaline" patented technology

Prodrugs of glutamine analogs are disclosed, such as the prodrugs of aza-serine and 6-diazo-5-oxo-norleucine (DON) and 5-diazo-4-oxo-L-norvaline (L-DONV).

This invention discloses a composition for enhancing oral umami perception and its application, belonging to the fields of food science and oral care technology. This composition amplifies umami signals in food by modulating the oral microenvironment of the user, mimicking the salivary biochemical characteristics of individuals with high umami sensitivity (UTS). The composition contains at least one active ingredient, preferably including: a) an umami perception enhancer, represented by valine, valine, cysteine, arginine, or glycine; and optionally including: b) a taste desensitization inhibitor, such as food-grade nitrates or cyclodextrins; c) an ionic environment modifier, such as calcium chloride or potassium phosphate; and d) a rheological property modifier, such as xanthan gum. This invention provides a novel umami enhancement technology pathway that, by improving taste perception efficiency rather than increasing additive dosage, maintains food flavor while possessing significant public health value.

A solid supplement composition comprising at least one non-ester nitrate compound and at least one isolated amino acid compound, wherein the at least one isolated amino acid compound is norvaline, wherein the at least one isolated amino acid compound is a separate compound than the at least one non-ester nitrate compound, and wherein the solid supplement composition comprises an amount of nitrate ion (NO3−) that is at least about 0.05625 mg. A semisolid supplement composition comprising at least one non-ester nitrate compound and at least one isolated amino acid compound, wherein the at least one isolated amino acid compound is norvaline, wherein the at least one isolated amino acid compound is a separate compound than the at least one non-ester nitrate compound, and wherein the semisolid supplement composition comprises an amount of nitrate ion (NO3−) that is at least about 0.05625 mg.

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to unit dose compositions comprising (a) L-ornithine or a pharmaceutically acceptable salt thereof; (b) L-norvaline or a pharmaceutically acceptable salt thereof; (c) agmatine or a pharmaceutically acceptable salt thereof; and (d) at least one of the following components: tongkat ali, Tribulus terrestris, horny goat weed, Panax notoginsing, maca root, lycopene, ashwagandha, or any combination thereof. In one aspect, the unit dose compositions can increase or enhance blood flow in a subject. In another aspect, the unit dose compositions can treat erectile dysfunction in a subject.

The invention belongs to the technical field of biology, and particularly discloses yarrowia lipolytica ILV6 protein mutants and application thereof. The ILV6 protein mutant is obtained by mutating the 81st glycine (Gly) of the amino acid sequence of the ILV6 protein of wild type yarrowia lipolytica. The method comprises the following steps: transforming a yarrowia lipolytica ILV6 protein mutant into a yarrowia lipolytica yeast to construct a yarrowia lipolytica recombinant strain; compared with the Yarrowia lipolytica recombinant engineering bacteria which do not express the Yarrowia lipolytica ILV6 protein mutant or express the wild type ILV6 protein or express the saccharomyces cerevisiae wild type ILV6 protein, the Yarrowia lipolytica recombinant engineering bacteria which express the Yarrowia lipolytica ILV6 protein mutant can tolerate DL-norvaline with relatively high concentration; in addition, the content of intracellular valine in the fermentation process can be obviously improved.

This invention relates to the fields of fluorescent contrast agents, radiopharmaceuticals, and nuclear medicine, specifically disclosing the application of a peptide TP-6 ​​in the preparation of tumor diagnostic and / or therapeutic reagents. The peptide TP-6 ​​is: D-Arg-L-Lys-L-Asp-L-Nva-D-Tyr, where D represents a non-natural D-type amino acid, L represents a natural L-type amino acid, and Nva is valine. The molecular probe constructed from the peptide TP-6 ​​of this invention can specifically target tumor sites and exhibits good uptake and retention capabilities at the tumor site, possessing a high target / non-target ratio. It is suitable for preparing intraoperative image-guided tumor diagnostic reagents and radiopharmaceuticals for tumor nuclear medicine diagnosis and precision radiotherapy.